Today's After-Hours Stock Movers:

Mereo BioPharma Group plc (NASDAQ: MREO) 30.3% HIGHER; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ: MREO) today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human monoclonal antibody that has shown the ability to improve bone production and density leading to greater bone strength in animal models of OI. Data from a Phase2b of setrusumab conducted by Mereo demonstrated a dose-dependent increase in bone formation, density, and strength in adults with OI.

DermTech, Inc. (NASDAQ: DMTK) 29.4% HIGHER; announced today the topline results from its TRUST Study of the companys non-invasive melanoma rule-out test, the Pigmented Lesion Assay (the PLA). The TRUST study is a long-term follow-up study of pigmented skin lesions that tested negative for melanoma with the PLA. It was designed to assess long-term outcomes of PLA negative tests and to further confirm the 99% negative predictive value (NPV) of the PLA. Specifically, the study protocol called for reevaluating and retesting lesions that were PLA negative 12 to 24 months prior to each subjects enrollment in the TRUST Study in order to determine the proportion of true negative lesions among those that tested negative. The PLA enhances early melanoma detection by assessing atypical pigmented lesions (lesions suspicious for melanoma) to help rule out melanoma and the need for surgical evaluation. The PLA detects LINC 518 (long intergenic non-protein coding RNA 518) and PRAME (preferentially expressed antigen in melanoma) as a 2-panel gene expression assay.

Scholastic Corp (NASDAQ: SCHL) 12.7% LOWER; reported Q2 EPS of $1.15, $0.23 worse than the analyst estimate of $1.38. Revenue for the quarter came in at $406 million versus the consensus estimate of $528 million.

Babcock & Wilcox (B&W) (NYSE: BW) 9% HIGHER; announced today that its B&W Thermal segment has booked new service projects valued at more than $10 million. These contracts, for utility and industrial facilities, are in addition to more than $30 million in construction services bookings recently announced by B&W.

Steelcase (NYSE: SCS) 7.3% LOWER; reported Q3 EPS of $0.08, $0.05 better than the analyst estimate of $0.03. Revenue for the quarter came in at $617.5 million versus the consensus estimate of $628.8 million. The company expects diluted earnings per share for the fourth quarter of fiscal 2021 to be approximately breakeven. The estimate includes: (1) projected operating expenses of between $180 million to $185 million, and (2) projected interest expense, net of investment income and other income, net, of approximately $5 million. Steelcase reported diluted earnings per share of $0.55, and adjusted earnings per share of $0.39, in the fourth quarter of fiscal 2020. (*Consensus sees Q3 EPS of $0.09 on revenue of $684.5 million)

Asure Software, Inc. (NASDAQ: ASUR) 5.4% LOWER; announced that it intends to offer and sell newly issued shares of its common stock in an underwritten public offering. Asure is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold by Asure in connection with the offering.

United States Steel Corporation (NYSE: X) 5.4% LOWER; today provided fourth quarter 2020 guidance. Fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million. The Company expects fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85). (*Consensus sees Q4 loss per share of $0.57).

FedEx (NYSE: FDX) 3.2% LOWER; reported Q2 EPS of $4.83, $0.82 better than the analyst estimate of $4.01. Revenue for the quarter came in at $20.6 billion versus the consensus estimate of $19.46 billion.

Moderna, Inc., (Nasdaq: MRNA) 3% LOWER; confirmed that the U.S. Food and Drug Administrations (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for the Companys COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended for EUA, 0 members voted against, and 1 abstained.

UPS (NYSE: UPS) 2% LOWER; down after FDX results.

SolarWinds (NYSE: SWI) 2% HIGHER; After the release of Orion 2020.2.1 HF2 on Tuesday night, they believe the Orion Platform now meets the US Federal and state agencies' requirements. We are providing direct support to these customers and will help them complete their upgrades quickly.